Cormorant Asset Management is a Boston-based investment manager with investment focus in both public and private market innovative companies in the biotechnology and life sciences marketplace.
Massachusetts, United States
|2018-10-19||TP Therapeutics||Mezzanine||$80M||Foresite Capital, HBM Healthcare Investments, Lilly Asia Ventures, Nextech Invest, OrbiMed Advisors, SR One, and venBIO|
|2018-09-12||Atreca||Series C||$125M||Aisling Capital, Boxer Capital, EcoR1 Capital, Redmile Group, Samsara BioCapital, Tekla Capital Management, and Wellington Management|
|2018-09-05||PhaseBio Pharmaceuticals||Series D||$34M||AstraZeneca, Fletcher Spaght Ventures, Hatteras Venture Partners, Johnson & Johnson Innovation, Mountain Group Capital, New Enterprise Associates, Rock Springs Capital, and Syno Capital|
|2018-08-13||Orchard Therapeutics||Series C||$150M||Agent Capital, ArrowMark Partners, Baillie Gifford & Co., Cowen Group, Deerfield Management, Driehaus Capital Management, Foresite Capital, Ghost Tree Capital Group, Medison Ventures, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Global Healthcare, Temasek Holdings, and Venrock|
|2018-07-24||Renovia||Series B||$32.3M||Ascension Ventures, ATON Partners, Inova Strategic Investments, Longwood Fund, OSF Ventures, Perceptive Advisors, and Western Technology Investment|